Ultragenyx (RARE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - Ultragenyx reported revenue of $164.88 million for the quarter ended December 2024, reflecting a 29.4% increase year-over-year [1] - The company's EPS was -$1.39, an improvement from -$1.52 in the same quarter last year [1] - Revenue exceeded the Zacks Consensus Estimate of $163.23 million by 1.01%, while EPS fell short of the consensus estimate of -$1.24 by 12.10% [1] Revenue Breakdown - Product sales for Dojolvi reached $31.10 million, surpassing the estimated $27.23 million, marking a 33.6% increase year-over-year [4] - Evkeeza generated $10.37 million, slightly below the $10.65 million estimate, but showed a significant year-over-year increase of 393.5% [4] - Mepsevii sales were reported at $7.98 million, below the average estimate of $8.91 million [4] - Total product sales amounted to $71.87 million, compared to the average estimate of $83 million, representing a 39.1% year-over-year increase [4] - Crysvita sales were $22.42 million, significantly lower than the estimated $35.76 million [4] - Non-cash collaboration royalty revenue was reported at $93.01 million, exceeding the average estimate of $71.60 million [4] Stock Performance - Ultragenyx shares have returned +6% over the past month, outperforming the Zacks S&P 500 composite's +3.9% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]